Advanced glycation end-product intermediaries and post-amadori inhibition
AssigneeKansas University Medical Center
InventorsBilly G. Hudson, Parvin Todd, Raja Gabriel Khalifah, Aaron Ashley Booth
Life of this patent
Estimating the term…
Abstract
The instant invention provides compositions and methods for modeling post-Amadori AGE formation and the identification and characterization of effective inhibitors of post-Amadori AGE formation, and such identified inhibitor compositions.
Claims20
A method for generating stable protein-sugar post-Amadori advanced glycation end-product (AGE) intermediates comprising incubating a protein with at least 0.015 M pentose sugar for sufficient length of time to generate stable post-Amadori AGE intermediates.
A method for rapidly generating antigenic post-Amadori advanced glycation endproduct comprising releasing a stable protein-sugar post-Amadori advanced glycation end-product intermediary from inhibitory conditions.
A method for inhibiting the conversion of Amadori compounds to post Amadori advanced glycation endproducts comprising administering to a mammal an effective amount of thiamine pyrophosphate to inhibit the conversion of Amadori compounds to post Amadori advanced glycation endproducts.
A method for inhibiting the conversion of Amadori compounds to post Amadori advanced glycation endproducts comprising administering an effective amount of pyridoxamine to inhibit the conversion of Amadori compounds to post Amadori advanced glycation endproducts wherein said effective amount of pyridoxamine is administered more than once.
A method for rapidly generating a rat model for diabetes with end-stage post-Amadori advanced glycation end-product related pathology comprising administering ribose to a rat at a dose of about 0.01 to 10 g/kg body weight per day.
A method for identifying an effective inhibitor of the formation of late Maillard products comprising:
- generating stable protein-sugar post-Amadori advanced glycation end-product (AGE) intermediates by incubating a protein with at least 0.015 M pentose sugar for sufficient length of time to generate stable post-Amadori AGE intermediates;
- contacting said stable protein-sugar post-Amadori advanced glycation end-product intermediates with an inhibitor candidate;
- identifying effective inhibition by monitoring the formation of post-Amadori AGEs after release of the stable protein-sugar post-Amadori advanced glycation end-product intermediates from sugar induced equilibrium by assay for post-Amadori AGE formation.
An effective inhibitor of post-Amadori advanced glycation end-product (AGE) formation, as characterized by the ability to inhibit the formation of post-Amadori AGE endproducts in an assay comprising:
- generating stable protein-sugar post-Amadori advanced glycation end-product intermediates by incubating a protein with at least 0.015 M pentose sugar for sufficient length of time to generate stable post-Amadori AGE intermediates;
- contacting said stable protein-sugar post-Amadori advanced glycation end-product intermediates with an inhibitor candidate;
- identifying effective inhibition by monitoring the formation of post-Amadori AGEs after release of the stable protein-sugar post-Amadori advanced glycation end-product intermediates from sugar induced equilibrium by assay for AGE formation.
A method for inhibiting the conversion of Amadori compounds to post Amadori advanced glycation endproducts comprising administering to a mammal having an elevated blood sugar level an effective amount of pyridoxamine to inhibit the conversion of Amadori compounds to post Amadori advanced glycation endproducts.
A method for preventing diabetic nephropathy comprising administering to a mammal having an elevated blood sugar level an effective amount of pyridoxamine to prevent diabetic nephropathy.
A method for treating diabetic nephropathy comprising administering to a mammal having an elevated blood sugar level an effective amount of pyridoxamine to treat diabetic nephropathy.
A method for inhibiting the conversion of Amadori compounds to post Amadori advanced glycation endproducts comprising administering to a mammal having an elevated blood sugar level an effective amount of thiamine pyrophosphate to inhibit the conversion of Amadori compounds to post Amadori advanced glycation endproducts.
Dependencies are inferred from the claim text.